Delivery of protein and peptide drugs in cancer:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
London
Imperial College
2006
Hackensack, NJ Distributed by World Scientific Pub. |
| Schlagworte: | |
| Online-Zugang: | Table of contents only Inhaltsverzeichnis |
| Beschreibung: | Includes bibliographical references and index |
| Beschreibung: | XVI, 375 S. Ill. 24 cm |
| ISBN: | 9781860946271 1860946275 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV036613249 | ||
| 003 | DE-604 | ||
| 005 | 20100826 | ||
| 007 | t | ||
| 008 | 100812s2006 xxka||| |||| 00||| eng d | ||
| 010 | |a 2007271998 | ||
| 015 | |a GBA655033 |2 dnb | ||
| 020 | |a 9781860946271 |9 978-1-86094-627-1 | ||
| 020 | |a 1860946275 |9 1-86094-627-5 | ||
| 035 | |a (OCoLC)255639567 | ||
| 035 | |a (DE-599)BVBBV036613249 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a xxk |c GB | ||
| 049 | |a DE-M49 | ||
| 050 | 0 | |a RS431.P38 | |
| 082 | 0 | |a 616.99/4061 | |
| 084 | |a CHE 820f |2 stub | ||
| 084 | |a CHE 893f |2 stub | ||
| 245 | 1 | 0 | |a Delivery of protein and peptide drugs in cancer |c [edited by] Vladimir P. Torchilin |
| 264 | 1 | |a London |b Imperial College |c 2006 | |
| 264 | 1 | |a Hackensack, NJ |b Distributed by World Scientific Pub. | |
| 300 | |a XVI, 375 S. |b Ill. |c 24 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 650 | 4 | |a Peptide drugs | |
| 650 | 4 | |a Cancer |x Chemotherapy | |
| 650 | 4 | |a Antineoplastic agents | |
| 650 | 4 | |a Drug delivery systems | |
| 650 | 4 | |a Neoplasms |x drug therapy | |
| 650 | 4 | |a Antineoplastic Agents | |
| 650 | 4 | |a Drug Delivery Systems | |
| 650 | 4 | |a Peptides |x therapeutic use | |
| 650 | 4 | |a Proteins |x therapeutic use | |
| 650 | 0 | 7 | |a Proteine |0 (DE-588)4076388-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Peptide |0 (DE-588)4045125-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Chemotherapeutikum |0 (DE-588)4009895-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Chemotherapeutikum |0 (DE-588)4009895-3 |D s |
| 689 | 0 | 2 | |a Proteine |0 (DE-588)4076388-2 |D s |
| 689 | 0 | 3 | |a Peptide |0 (DE-588)4045125-2 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 700 | 1 | |a Torčilin, Vladimir P. |d 1946- |e Sonstige |0 (DE-588)112659381 |4 oth | |
| 856 | 4 | |u http://www.loc.gov/catdir/toc/fy1001/2007271998.html |3 Table of contents only | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020533454&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-020533454 | ||
Datensatz im Suchindex
| _version_ | 1804143219699613696 |
|---|---|
| adam_text | Contents
Contributors xiii
1. Introduction 1
Vladimir Torchilin
References 6
2. Influence of Tumor Physiology on Delivery of Therapeutics 9
Robert B. Campbell
1. Introduction 9
2. Blood Vessels: Modulation of Normal and
Pathologic Function 10
2.1. General features of blood vessels
in biological systems 10
2.2. The tumor vasculature: Specialized features
and angiogenesis 12
3. Transport of Peptide and Protein Molecules across Tumor
Capillary Networks 14
3.1. Barriers limiting drug transport 14
V
vi Contents
3.2. The interstitial matrix: MMPs, collagen, invasion and
metastasis 19
3.3. Overcoming barriers: Exploiting tumor physiology for
therapeutic gain 21
4. Concluding Remarks 29
References 29
3. Enhanced Permeability and Retention (EPR) Effect
and Tumor-Selective Delivery of Anticancer Drugs 37
Khaled Greish, Arun K. Iyer, Jun Fang, Michio Kawasuji and
Hiroshi Maeda
1. Introduction 37
2. Theory Underlying the EPR Effect 38
3. Anatomical and Pathophysiological Abnormalities Related
to EPR Effect 39
4. Augmentation of the EPR Effect in Solid Tumor
by Influencing Vascular Mediators 42
5. Relation of Fluid Dynamics in Cancer Tissue
to the EPR Effect 44
6. Implications for Delivery of Drugs to Tumors 45
7. Conclusion 48
References 48
4. Basic Strategies for PEGylation of Peptide and Protein Drugs 53
Gianfranco Pasut, Margherita Morpurgo and Francesco M. Veronese
1. Introduction 54
2. Features of PEG as Bioconjugation Polymer 55
3. PEGylation Chemistry 61
3.1. Amino group PEGylation 61
3.2. Thiol PEGylation 67
3.3. Carboxy PEGylation 68
4. Strategies in Protein PEGylation 69
5. Enzymatic Approach for Protein PEGylation 74
6. PEGylated Protein Purification and Characterization 76
7. Conclusion 78
References 79
Contents vii
5. PEGylated Proteins as Cancer Therapeutics 85
Margherita Morpurgo, Gianfranco Pasut and Francesco M. Veronese
1. Introduction 85
2. Enzymes and PEG-Enzymes in Cancer Therapy 87
2.1. Metabolite depleting enzymes 88
2.1.1. PEG-asparaginase (PEG-ASNase) 88
2.1.2. PEG-methioninase (PEG-METase) 91
2.1.3. PEG-arginine deiminase (PEG-ADI) 93
2.1.4. PEG-uricase (PEG-UK) 95
3. PEG-Antibodies 100
4. Conclusions 103
References 104
6. PEGylated Proteins in Immunotherapy of Cancer 111
James F. Eliason
1. Introduction 112
2. PEGylated Interferon-a 114
3. PEGylated G-CSF 115
4. Other PEGylated Hematopoietic Growth Factors 117
5. PEGylated Lymphokines 118
6. PEGylated Cytokine Inhibitors 119
7. Conclusions and Outlook 119
References 120
7. Silencing Proteins: Nanotechnological Approaches
to Deliver siRNA for Cancer Therapy 127
Raymond M. Schiffelers, Daan j.A. Crommelin and Gert Storm
1. Role of Proteins in Tumor Development 128
1.1. Proto-oncogenes 128
1.2. Tumor suppressor genes 128
1.3. Pro-angiogenic proteins/pro-metastatic proteins . . . . 129
1.4. Proteins involved in drug resistance 129
2. RNA Interference 129
2.1. Mechanism of RNA interference 130
2.2. Structural requirements for siRNA 131
3. Approaches for siRNA Delivery 134
viii Contents
4. siRNA Delivery for Cancer Therapy 135
4.1. siRNA to silence oncogenes 135
4.2. siRNA to silence mutated tumor suppressor genes . . . 138
4.3. siRNA to silence pro-angiogenic/
pro-metastatic genes 139
4.4. siRNA to silence genes that increase tumor
drug resistance 141
5. Concluding Remarks 141
References 143
8. Anti-Cancer Proteins and Peptides in Liposomes 155
Vladimir Torchilin
1. Proteins and Peptides as Cancer Therapeutics 155
2. Stability, Delivery and Distribution Issues for Peptide
and Protein Drugs 156
3. Possible Solutions. Liposomes as
Pharmaceutical Carriers 158
4. Liposomal Proteins and Peptides for Cancer Treatment . . . 162
5. Tumor Cell Targeting Using Specific
Ligand-Bearing Liposomes 165
6. Transmembrane Delivery of Protein and Peptide Drugs
into Tumor Cells 167
References 171
9. Folate-Mediated Delivery of Protein and Peptide
Drugs into Tumors 183
Joseph A. Reddy, Christopher P. Leamon and Philip S. Low
1. Introduction 184
2. Methods for Coupling FA to Proteins and Peptides 185
3. Cytotoxicity Studies of Folate Linked Toxins 188
4. Folate Targeted Immunotherapy 192
5. Folate Targeted Enzyme Prodrug Therapy 195
6. Folate-mediated Targeting of Adenovirus 195
7. In vivo Fate of Folate-protein Conjugates 197
8. Folate-targeted Peptidic Imaging Agent 198
9. Conclusions and Outlook 200
References 201
Contents ix
10. Transf errin Receptor Mediated Delivery of Protein
and Peptide Drugs into Tumors 205
Julia Fahrmeir and Manfred Ogris
1. Introduction 205
2. Transferrin(Tf) 206
2.1. Structure 206
2.2. Biological function 207
3. Transferrin-Receptors (TfR) 207
3.1. Structure 207
3.2. Clathrin-mediated endocytosis 208
3.3. Regulation of expression 209
3.4. Tissue distribution 209
4. In vivo Application of Proteins Drugs,
General Considerations 210
5. Generation of Conjugates 211
5.1. Chemical coupling 211
5.2. Recombinant production of conjugates 212
6. Tf and AntiTFR Targeted Toxins 213
6.1. Ribosomal inhibitors 213
6.2. Ribonucleases 214
6.3. Diphtheria toxin and Pseudomonas exotoxin 215
7. Conclusions 217
References 217
11. Transmembrane Delivery of Protein and Peptide Drugs
into Cancer Cells 225
Cheryl C. Saenz and Steven F. Dowdy
1. Introduction 226
2. Functional Characteristics of Protein
Transduction Domains 227
2.1. TAT peptide 227
2.2. TAT-related peptides 227
3. Mechanism of PTD-Mediated Transduction 228
4. Delivery of Anti-Cancer Therapies Using Protein
Transduction Domains 229
x Contents
4.1. Loss of tumor suppressor function 230
4.1.1. p53 tumor suppressor 230
4.1.2. pl6 tumor suppressor 232
4.1.3. p21 and p27 tumor suppressors 232
4.1.4. VHL tumor suppressor 234
4.1.5. NF2/merlin tumor suppressor 234
4.2. Resistance to apoptosis 235
4.2.1. Caspase activation 235
4.2.2. Bcl-2 family proteins 237
4.2.3. SI00 family proteins 237
4.2.4. Protein kinase 2 (casein kinase 2) 238
4.2.5. Activating transcription factor 2 238
4.3. Activation of oncogenes 239
4.3.1. Ras signaling pathways 239
4.3.2. HER-2 pathway 240
4.4. Resistance to conventional cancer therapeutics .... 241
4.4.1. RasGAP-derived peptide 241
4.4.2. Repair of mitochondrial DNA 242
4.5. Additional applications of PTD-mediated delivery in
the treatment of cancer cells 243
4.5.1. Cancer cell vaccines 243
4.5.2. Cancer cell migration 244
5. Conclusions • 245
References ¦ 245
12. Protein and Peptide Drugs to Suppress Tumor Angiogenesis 255
Curzio Riiegg
1. Introduction ¦ 255
2. Natural Cyokines • 256
3. Cryptic Protein Fragments • 262
4. Antibodies • 264
4.1. Monoclonal antibodies (mAb) 264
4.2. Recombinant antibodies 267
5. Soluble VEGF-Rs (Traps) . • 269
6. Small Peptides • 269
6.1. Vascular targeting peptides 269
Contents xi
6.2. Function-blocking peptides 271
7. Conclusions and Perspectives 273
References 273
13. Utilizing Lymphatic Transport in Enhancing the Delivery
of Drugs, Including Proteins, and Peptides,
to Metastatic Tumors 285
Ellen K. Wasan and Kishor M. Wasan
1. Introduction 286
2. Lipid Absorption from the Small Intestine and the
Lymphatic System 287
2.1. Lipid absorption from the small intestine 287
2.2. Intestinal lymphatic system 290
3. Lymphatic Vessels Functioning as Transport Routes
for Malignant Cells 290
4. Biological and Pharmaceutical Factors Affecting
Lymphatic Drug Delivery 291
4.1. Contribution of lymphatic transport to the increased
absorption of water-insoluble drugs into the systemic
circulation 291
4.2. Evaluation and assessment of intestinal lymphatic
transport 293
4.3. Proposed mechanisms that govern the lymphatic
transport of water-insoluble drugs 295
4.3.1. Diffusion and partition behavior of
water-insoluble drugs 295
4.3.2. Lipid solubility of water-insoluble drugs .... 296
5. Utilization of Lymphatic System in the Delivery of Drugs,
Including Proteins and Peptides to Metastatic Tumors . . . 297
6. Clinical Significance 300
References 301
14. Delivery of Protein and Peptide Drugs to Brain Tumors 309
Herbert B. Newton
1. Introduction 310
2. Biology of the BBB, BBB-Transport Systems, and BTB .... 311
xii Contents
3. Overview of Drug Delivery and Distribution 314
4. Chemical Modification, Glycosylation, Pegylation, and
Other Delivery Approaches 315
5. Nanoparticle Drug Delivery Approaches 318
6. Liposomal Drug Delivery Approaches 320
7. Convection-Enhanced Delivery Approaches 323
8. Immunoglobulin-Based Delivery Approaches 323
9. Vector-Mediated Delivery Approaches 326
References 328
15. Protein and Peptide-Based Cancer Gene Therapy 335
Sunil Chada and Rajagopal Ramesh
1. Cancer Gene Therapy 335
1.1. Identifying the target gene/pathway
for cancer therapy 336
1.2. Selection of gene therapy vector 338
2. Protein-Based Cancer Gene Therapy 339
2.1. Growth inhibition and apoptosis 340
2.1.1. Toxic proteins 340
2.1.2. Tumor suppressor proteins 343
2.1.3. Antiangiogenic proteins 348
2.2. Enhancement of the immune response 351
3. Peptide-Based Cancer Gene Therapy 353
3.1. Tumor targeting and gene transduction 353
4. Conclusions 357
References 357
Index 371
|
| any_adam_object | 1 |
| author_GND | (DE-588)112659381 |
| building | Verbundindex |
| bvnumber | BV036613249 |
| callnumber-first | R - Medicine |
| callnumber-label | RS431 |
| callnumber-raw | RS431.P38 |
| callnumber-search | RS431.P38 |
| callnumber-sort | RS 3431 P38 |
| callnumber-subject | RS - Pharmacy |
| classification_tum | CHE 820f CHE 893f |
| ctrlnum | (OCoLC)255639567 (DE-599)BVBBV036613249 |
| dewey-full | 616.99/4061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4061 |
| dewey-search | 616.99/4061 |
| dewey-sort | 3616.99 44061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02370nam a2200625zc 4500</leader><controlfield tag="001">BV036613249</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20100826 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">100812s2006 xxka||| |||| 00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2007271998</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">GBA655033</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781860946271</subfield><subfield code="9">978-1-86094-627-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1860946275</subfield><subfield code="9">1-86094-627-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)255639567</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV036613249</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxk</subfield><subfield code="c">GB</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-M49</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS431.P38</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4061</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CHE 820f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CHE 893f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Delivery of protein and peptide drugs in cancer</subfield><subfield code="c">[edited by] Vladimir P. Torchilin</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London</subfield><subfield code="b">Imperial College</subfield><subfield code="c">2006</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hackensack, NJ</subfield><subfield code="b">Distributed by World Scientific Pub.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVI, 375 S.</subfield><subfield code="b">Ill.</subfield><subfield code="c">24 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptide drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug delivery systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Delivery Systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptides</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Proteins</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Proteine</subfield><subfield code="0">(DE-588)4076388-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Peptide</subfield><subfield code="0">(DE-588)4045125-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapeutikum</subfield><subfield code="0">(DE-588)4009895-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Chemotherapeutikum</subfield><subfield code="0">(DE-588)4009895-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Proteine</subfield><subfield code="0">(DE-588)4076388-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Peptide</subfield><subfield code="0">(DE-588)4045125-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Torčilin, Vladimir P.</subfield><subfield code="d">1946-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)112659381</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2=" "><subfield code="u">http://www.loc.gov/catdir/toc/fy1001/2007271998.html</subfield><subfield code="3">Table of contents only</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020533454&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-020533454</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV036613249 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T22:44:11Z |
| institution | BVB |
| isbn | 9781860946271 1860946275 |
| language | English |
| lccn | 2007271998 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-020533454 |
| oclc_num | 255639567 |
| open_access_boolean | |
| owner | DE-M49 DE-BY-TUM |
| owner_facet | DE-M49 DE-BY-TUM |
| physical | XVI, 375 S. Ill. 24 cm |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Imperial College Distributed by World Scientific Pub. |
| record_format | marc |
| spelling | Delivery of protein and peptide drugs in cancer [edited by] Vladimir P. Torchilin London Imperial College 2006 Hackensack, NJ Distributed by World Scientific Pub. XVI, 375 S. Ill. 24 cm txt rdacontent n rdamedia nc rdacarrier Includes bibliographical references and index Peptide drugs Cancer Chemotherapy Antineoplastic agents Drug delivery systems Neoplasms drug therapy Antineoplastic Agents Drug Delivery Systems Peptides therapeutic use Proteins therapeutic use Proteine (DE-588)4076388-2 gnd rswk-swf Peptide (DE-588)4045125-2 gnd rswk-swf Chemotherapeutikum (DE-588)4009895-3 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Krebs Medizin (DE-588)4073781-0 s Chemotherapeutikum (DE-588)4009895-3 s Proteine (DE-588)4076388-2 s Peptide (DE-588)4045125-2 s b DE-604 Torčilin, Vladimir P. 1946- Sonstige (DE-588)112659381 oth http://www.loc.gov/catdir/toc/fy1001/2007271998.html Table of contents only HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020533454&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Delivery of protein and peptide drugs in cancer Peptide drugs Cancer Chemotherapy Antineoplastic agents Drug delivery systems Neoplasms drug therapy Antineoplastic Agents Drug Delivery Systems Peptides therapeutic use Proteins therapeutic use Proteine (DE-588)4076388-2 gnd Peptide (DE-588)4045125-2 gnd Chemotherapeutikum (DE-588)4009895-3 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| subject_GND | (DE-588)4076388-2 (DE-588)4045125-2 (DE-588)4009895-3 (DE-588)4073781-0 (DE-588)4143413-4 |
| title | Delivery of protein and peptide drugs in cancer |
| title_auth | Delivery of protein and peptide drugs in cancer |
| title_exact_search | Delivery of protein and peptide drugs in cancer |
| title_full | Delivery of protein and peptide drugs in cancer [edited by] Vladimir P. Torchilin |
| title_fullStr | Delivery of protein and peptide drugs in cancer [edited by] Vladimir P. Torchilin |
| title_full_unstemmed | Delivery of protein and peptide drugs in cancer [edited by] Vladimir P. Torchilin |
| title_short | Delivery of protein and peptide drugs in cancer |
| title_sort | delivery of protein and peptide drugs in cancer |
| topic | Peptide drugs Cancer Chemotherapy Antineoplastic agents Drug delivery systems Neoplasms drug therapy Antineoplastic Agents Drug Delivery Systems Peptides therapeutic use Proteins therapeutic use Proteine (DE-588)4076388-2 gnd Peptide (DE-588)4045125-2 gnd Chemotherapeutikum (DE-588)4009895-3 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| topic_facet | Peptide drugs Cancer Chemotherapy Antineoplastic agents Drug delivery systems Neoplasms drug therapy Antineoplastic Agents Drug Delivery Systems Peptides therapeutic use Proteins therapeutic use Proteine Peptide Chemotherapeutikum Krebs Medizin Aufsatzsammlung |
| url | http://www.loc.gov/catdir/toc/fy1001/2007271998.html http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=020533454&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT torcilinvladimirp deliveryofproteinandpeptidedrugsincancer |